|By Business Wire||
|June 2, 2014 04:14 PM EDT||
VuCOMP today announced that it will expand its salesforce to take advantage of growing market opportunity for its automated M-Vu Breast Density and M-Vu CAD products. The company will concurrently develop strategic sales and distribution partnerships to reach and penetrate the burgeoning market.
“Some 17 states now have breast density notification legislation in effect covering roughly half of the U.S. population, and more states have legislation pending,” said Kathleen Kelly, VuCOMP Director of Sales. “As a result we have seen a growing demand to provide a best breast care for all patients, including those patients with dense breast tissue. Our customers know with M-Vu Breast Density and M-Vu CAD, they have a full suite of tools available to provide excellent care for all patients. These also make their clinics more efficient and that’s a very powerful combination.”
In addition to expansion in the U.S., VuCOMP will focus on growing its installed base in Europe and Asia where it currently has customers.
VuCOMP COO Barry Burgdorf stated that, "Given the fact that we've had such positive validation here and abroad and that the market opportunity is so substantial, putting more resources into sales is a logical move for us at this stage of company growth.”
M-Vu CAD received FDA approval for digital mammography in October 2012. While mammography CAD systems have been FDA-approved since 1998, recent FDA guidelines have significantly raised the bar for demonstrating CAD effectiveness, and now recommend comprehensive reader studies proving that radiologists are more effective when they use CAD. The VuCOMP system is the first mammography CAD product in the world to achieve FDA approval under these clinical study guidelines. M-Vu Breast Density received FDA approval in December 2013 and is being installed in clinics around the world.
About VuCOMP, Inc.
VuCOMP, Inc. leads the way in setting a new standard for CAD and automated breast density measurement. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.